In the corresponding mutant murine HCC model mice (Figure 7D), puerarin treatment conferred no survival benefit (Figure 7E), nor did it reduce tumor burden (Figure 7F–H) or suppress Ti‐Treg infiltration (Figure 7I, J), indicating that MIC19 mutation abrogates the therapeutic efficacy of puerarin in vivo. This evidence concerns the gene CHCHD3 and neoplasm.